Targeting a Prokaryotic Protein in a Eukaryotic Pathogen: Identification of Lead Compounds against Cryptosporidiosis (DOI:10.1016/j.chembiol.2007.12.010);Targeting a Prokaryotic Protein in a Eukaryotic Pathogen: Identification of Lead Compounds against Cryptosporidiosis

Chemistry and Biology

Volumn 15, Issue 1, 2008, Pages 70-77

  Umejiego, Nwakaso N ^a,b   Gollapalli, Deviprasad ^a   Sharling, Lisa ^b   Volftsun, Anna ^a   Lu, Jennifer ^a   Benjamin, Nicole N ^a   Stroupe, Adam H ^b   Riera, Thomas V ^a   Striepen, Boris ^b   Hedstrom, Lizbeth ^a  

^a BRANDEIS UNIVERSITY   (United States)

^b UNIVERSITY OF GEORGIA   (United States)

Author keywords

CHEMBIO; PROTEINS

Indexed keywords

BACTERIA (MICROORGANISMS); CRYPTOSPORIDIUM PARVUM; EUKARYOTA; PROKARYOTA;

EID: 38349082511     PISSN: 10745521     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.chembiol.2008.02.007     Document Type: Erratum

References (36)

1. Abrahamsen M.S., Templeton T.J., Enomoto S., Abrahante J.E., Zhu G., Lancto C.A., Deng M., Liu C., Widmer G., Tzipori S., et al. Complete genome sequence of the apicomplexan, Cryptosporidium parvum. Science 304 (2004) 441-445
2. Abubakar I., Aliyu S.H., Arumugam C., Usman N.K., and Hunter P.R. Treatment of cryptosporidiosis in immunocompromised individuals: systematic review and meta-analysis. Br. J. Clin. Pharmacol. 63 (2007) 387-393
3. Arrowood M.J. In vitro cultivation of Cryptosporidium species. Clin. Microbiol. Rev. 15 (2002) 390-400
4. Berkman D.S., Lescano A.G., Gilman R.H., Lopez S.L., and Black M.M. Effects of stunting, diarrhoeal disease, and parasitic infection during infancy on cognition in late childhood: a follow-up study. Lancet 359 (2002) 564-571
5. Cai X., Woods K.M., Upton S.J., and Zhu G. Application of quantitative real-time reverse transcription-PCR in assessing drug efficacy against the intracellular pathogen Cryptosporidium parvum in vitro. Antimicrob. Agents Chemother. 49 (2005) 4437-4442
6. Carey C.M., Lee H., and Trevors J.T. Biology, persistence and detection of Cryptosporidium parvum and Cryptosporidium hominis oocyst. Water Res. 38 (2004) 818-862
7. Cleland W.W. The kinetics of enzyme-catalyzed reactions with two or more substrates or products. II. Inhibition: nomenclature and theory. Biochim. Biophys. Acta 67 (1963) 173-187
8. Corso P.S., Kramer M.H., Blair K.A., Addiss D.G., Davis J.P., and Haddix A.C. Cost of illness in the 1993 waterborne Cryptosporidium outbreak, Milwaukee, Wisconsin. Emerg. Infect. Dis. 9 (2003) 426-431
9. Digits J.A., and Hedstrom L. Kinetic mechanism of Tritrichomonas foetus inosine-5′-monophosphate dehydrogenase. Biochemistry 38 (1999) 2295-2306
10. DuPont H.L., Chappell C.L., Sterling C.R., Okhuysen P.C., Rose J.B., and Jakubowski W. The infectivity of Cryptosporidium parvum in healthy volunteers. N. Engl. J. Med. 332 (1995) 855-859
11. Farazi T., Leichman J., Harris T., Cahoon M., and Hedstrom L. Isolation and characterization of mycophenolic acid resistant mutants of inosine 5′-monophosphate dehydrogenase. J. Biol. Chem. 272 (1997) 961-965
12. Fayer R. Cryptosporidium: a water-borne zoonotic parasite. Vet. Parasitol. 126 (2004) 37-56
13. Griffiths J.K., Balakrishnan R., Widmer G., and Tzipori S. Paromomycin and geneticin inhibit intracellular Cryptosporidium parvum without trafficking through the host cell cytoplasm: implications for drug delivery. Infect. Immun. 66 (1998) 3874-3883
14. Gut J., and Nelson R.G. Cryptosporidium parvum: lectins mediate irreversible inhibition of sporozoite infectivity in vitro. J. Eukaryot. Microbiol. 46 (1999) 48S-49S
15. Gut J., and Nelson R.G. Cryptosporidium parvum: synchronized excystation in vitro and evaluation of sporozoite infectivity with a new lectin-based assay. J. Eukaryot. Microbiol. 46 (1999) 56S-57S
16. Hashim A., Clyne M., Mulcahy G., Akiyoshi D., Chalmers R., and Bourke B. Host cell tropism underlies species restriction of human and bovine Cryptosporidium parvum genotypes. Infect. Immun. 72 (2004) 6125-6131
17. Hashim A., Mulcahy G., Bourke B., and Clyne M. Interaction of Cryptosporidium hominis and Cryptosporidium parvum with primary human and bovine intestinal cells. Infect. Immun. 74 (2006) 99-107
18. Hedstrom L., and Gan L. IMP dehydrogenase: structural schizophrenia and an unusual base. Curr. Opin. Chem. Biol. 10 (2006) 520-525
19. Hedstrom L., Cheung K., and Wang C.C. A novel mechanism of mycophenolic acid resistance in the protozoan parasite Tritrichomonas foetus. Biochem. Pharmacol. 39 (1990) 151-160
20. Huang D.B., and White A.C. An updated review on Cryptosporidium and Giardia. Gastroenterol. Clin. North Am. 35 (2006) 291-314
21. Huang D.B., Chappell C., and Okhuysen P.C. Cryptosporidiosis in children. Semin. Pediatr. Infect. Dis. 15 (2004) 253-259
22. Mead J.R. Cryptosporidiosis and the challenges of chemotherapy. Drug Resist. Updat. 5 (2002) 47-57
23. Moriarty E.M., Duffy G., McEvoy J.M., Caccio S., Sheridan J.J., McDowell D., and Blair I.S. The effect of thermal treatments on the viability and infectivity of Cryptosporidium parvum on beef surfaces. J. Appl. Microbiol. 98 (2005) 618-623
24. Mortimer S.E., and Hedstrom L. Autosomal dominant retinitis pigmentosa mutations in inosine 5′-monophosphate dehydrogenase type I disrupt nucleic acid binding. Biochem. J. 390 (2005) 41-47
25. Perkins M.E., Wu T.W., and Le Blancq S.M. Cyclosporin analogs inhibit in vitro growth of Cryptosporidium parvum. Antimicrob. Agents Chemother. 42 (1998) 843-848
26. Pettersen E.F., Goddard T.D., Huang C.C., Couch G.S., Greenblatt D.M., Meng E.C., and Ferrin T.E. UCSF Chimera-a visualization system for exploratory research and analysis. J. Comput. Chem. 25 (2004) 1605-1612
27. Ratcliffe A.J. Inosine 5′-monophosphate dehydrogenase inhibitors for the treatment of autoimmune diseases. Curr. Opin. Drug Discov. Dev. 9 (2006) 595-605
28. Striepen B., White M.W., Li C., Guerini M.N., Malik S.B., Logsdon Jr. J.M., Liu C., and Abrahamsen M.S. Genetic complementation in apicomplexan parasites. Proc. Natl. Acad. Sci. USA 99 (2002) 6304-6309
29. Striepen B., Pruijssers A.J., Huang J., Li C., Gubbels M.J., Umejiego N.N., Hedstrom L., and Kissinger J.C. Gene transfer in the evolution of parasite nucleotide biosynthesis. Proc. Natl. Acad. Sci. USA 101 (2004) 3154-3159
30. Templeton T.J., Iyer L.M., Anantharaman V., Enomoto S., Abrahante J.E., Subramanian G.M., Hoffman S.L., Abrahamsen M.S., and Aravind L. Comparative analysis of apicomplexa and genomic diversity in eukaryotes. Genome Res. 14 (2004) 1686-1695
31. Umejiego N.N., Li C., Riera T., Hedstrom L., and Striepen B. Cryptosporidium parvum IMP dehydrogenase: identification of functional, structural and dynamic properties that can be exploited for drug design. J. Biol. Chem. 279 (2004) 40320-40327
32. Upton S.J. In vitro cultivation. In: Fayer R. (Ed). Cryptosporidium and Cryptosporidiosis (1997), CRC Press, Boca Raton, FL 181-207
33. Winter G., Gooley A.A., Williams K.L., and Slade M.B. Characterization of a major sporozoite surface glycoprotein of Cryptosporidum parvum. Funct. Integr. Genomics 1 (2000) 207-217
34. Woods K.M., Nesterenko M.V., and Upton S.J. Development of a microtitre ELISA to quantify development of Cryptosporidium parvum in vitro. FEMS Microbiol. Lett. 128 (1995) 89-94
35. Xu P., Widmer G., Wang Y., Ozaki L.S., Alves J.M., Serrano M.G., Puiu D., Manque P., Akiyoshi D., Mackey A.J., et al. The genome of Cryptosporidium hominis. Nature 431 (2004) 1107-1112
36. You X., Arrowood M.J., Lejkowski M., Xie L., Schinazi R.F., and Mead J.R. A chemiluminescence immunoassay for evaluation of Cryptosporidium parvum growth in vitro. FEMS Microbiol. Lett. 136 (1996) 251-256